PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Drug Discovery: Solving the Structure of an Anti-hypertension Drug Target
July 2015
Retrospective: 7,000 Structures Closer to Understanding Biology
July 2015
Families in Gene Neighborhoods
June 2015
Channels and Transporters: BEST in Show
April 2015
Channels and Transporters: Reorienting a Peptide in the Pocket
April 2015
Ryanodine Receptor
April 2015
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
Protein Folding and Misfolding: Refolding in Membrane Mimetic
March 2015
Nuclear Pore Complex: A Flexible Transporter
February 2015
Nuclear Pore Complex: Higher Resolution of Macromolecules
February 2015
Nuclear Pore Complex: Integrative Approach to Probe Nup133
February 2015
Piecing Together the Nuclear Pore Complex
February 2015
Mitochondrion: Flipping for UCP2
December 2014
Transmembrane Spans
December 2014
Glucagon Receptor
April 2014
Membrane Proteome: A Cap on Transport
April 2014
Membrane Proteome: Microcrystals Yield Big Data
April 2014
Membrane Proteome: Pumping Out Heavy Metal
April 2014
Design and Discovery: Virtual Drug Screening
January 2014
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Microbiome: Solid-State NMR, Crystallized
September 2013
CAAX Endoproteases
August 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Membrane Proteome: Making DNA Nanotubes for NMR Structure Determination
August 2013
Membrane Proteome: Unveiling the Human α-helical Membrane Proteome
August 2013
Cell-Cell Interaction: Magic Structure from Microcrystals
March 2013
Cell-Cell Interaction: Nanoparticles in Cell Camouflage
March 2013
Membrane Proteome: Capturing Multiple Conformations
December 2012
Membrane Proteome: Soft Sampling
December 2012
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
Membrane Proteome: Tuning Membrane Protein Expression
December 2012
Cytochrome Oxidase
November 2012
Membrane Proteome: Building a Carrier
November 2012
Membrane Proteome: Every Protein Has Its Tag
November 2012
Membrane Proteome: Specific vs. Non-specific weak interactions
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Insert Here
October 2012
Solute Channels
September 2012
To structure, faster
August 2012
Pocket changes
July 2012
Predictive protein origami
July 2012
G Protein-Coupled Receptors
May 2012
Twist to open
March 2012
Anchoring's the way
February 2012
Overexpressed problems
February 2012
Gentle membrane protein extraction
January 2012
Docking and rolling
October 2011
A fragmented approach to membrane protein structures
September 2011
Raising a glass to GLIC
August 2011
Sugar transport
June 2011
A2A Adenosine Receptor
May 2011
TrkH Potassium Ion Transporter
April 2011
Subtly different
March 2011
A new amphiphile for crystallizing membrane proteins
January 2011
CXCR4
January 2011
Guard cells pick up the SLAC
December 2010
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Formate transporter or channel?
March 2010
Tips for crystallizing membrane proteins in lipidic mesophases
February 2010
Urea transporter
February 2010
Five good reasons to use single protein production for membrane proteins
January 2010
Membrane proteins spotted in their native habitat
January 2010
Spot the pore
January 2010
Get3 into the groove
October 2009
GPCR subunits: Separate but not equal
September 2009
GPCR modeling: any good?
August 2009
Surviving in an acid environment
August 2009
Tips for crystallizing membrane proteins
June 2009
You look familiar: the Type VI secretion system
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Aquaglyceroporin
March 2009
Death clusters
March 2009
Protein nanopores
March 2009
Transporter mechanism in sight
February 2009
A pocket guide to GPCRs
December 2008
Tuning membrane protein overexpression
October 2008
Blocking AmtB
September 2008

Research Themes Membrane proteins

Drug Discovery: Modeling NET Interactions

SBKB [doi:10.1038/sbkb.2012.164]
Featured Article - October 2013
Short description: A structural model of the norepinephrine transporter is used in a virtual ligand screen to identify new drug interactions.

Predicted NET binding pocket and norepinephrine-binding mode. NET structure is drawn as white ribbons with key residues in sticks; norepinephrine is drawn in orange. Figure courtesy of Avner Schlessinger.

Sodium:neurotransmitter symporters (solute carriers 6, SLC6) form a family of ion-dependent transporter proteins that regulate a variety of biological activities through the uptake of neurotransmitters, osmolytes and amino acids into the cell. The norepinephrine transporter (NET) is responsible for the recycling of the neurotransmitter norepinephrine from the synaptic space into presynaptic neurons. NET mutations are associated with several behavioral disorders. NET is the target of drugs treating depression, anxiety and attention-deficit hyperactivity disorder, and may also mediate side effects from other prescription drugs. Many of these drugs are actually inhibitors of NET, preventing the reuptake of norepinephrine.

Schlessinger, Sali and colleagues (PSI CSMP and EFI) have employed a structure-based screening strategy to examine prescription drugs that may bind to NET. The authors generated a comparative model of NET based on the structure of the bacterial homolog LeuT (PDB 2A65), a leucine transporter from Aquifex aeolicus, and then validated the model by docking known NET ligands within the binding pocket. The modeled binding pocket is small and lined with several hydrophobic residues; additional key polar interactions were predicted from the docked NET-ligand complexes.

Next, a filtered set from the library of known drugs in the Kyoto Encyclopedia of Genes and Genomes was computationally screened against the NET model. Encouragingly, several known NET binders ranked highly within the screen. The authors manually analyzed the 200 highest-ranking hits and selected 18 novel drugs for experimental testing of the inhibition of [3H]norepinephrine uptake by NET in human embryonic kidney cells. These 18 were parsed into a “high-confidence” group, having a predicted binding mode nearly identical to norepinephrine, and a second “medium-confidence” group, having a dissimilar predicted binding mode and forming only one key polar interaction within the binding pocket. All members of the high-confidence group—which include a monoamine oxidase inhibitor, a nasal decongestant, an antidepressant and two adrenergic agents— showed significant levels of inhibition, as did several drugs in the medium-confidence group. In particular, two medium-confidence hits, an antidiabetic drug and a nasal decongestant, were shown to be potent inhibitors of NET activity.

Pharmacologically, the findings suggest that the characterized efficacy of some neuroactive drugs may be due to their ability to inhibit NET in addition to their intended target. Further, drugs used to treat conditions unrelated to NET activity (for example, diabetes) may produce side effects caused by NET inhibition. Finally, the modeling and docking methodology may be a promising approach to characterize unknown drug interactions with other membrane receptors and transporters.

Michelle Montoya

References

  1. A. Schlessinger et al. Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET.
    Proc Natl Acad Sci U S A. 108, 15810-15815 (2011). doi:10.1073/pnas.1106030108

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health